Pureos Bioventures

What Pureos Bioventures does

Pureos Bioventures (legally Pureos Partners AG) is a Swiss venture capital firm founded in 2017 and headquartered in Pfäffikon, Switzerland, that invests in private innovative drug development companies with an emphasis on the next generation of biological drugs and drug formats, including antibody-drug conjugates (ADCs), T-cell receptor therapies, radiopharmaceuticals, and gene therapies. The firm is led by founding partners Dr. Dominik Escher, Dr. Klaus Breiner, and Dr. Martin Münchbach, alongside a broader team of venture partners, an advisory board of KOLs, and Guernsey-based fund directors, and manages approximately 18-19 active portfolio companies across oncology, fibrosis, ophthalmology, cardiology, infectious disease, and neurology.

The firm raised and expanded a venture capital fund to USD 205 million as of April 2021 and received a FINMA Portfolio Manager license in November 2022, enabling regulated portfolio management under Swiss financial supervision. Pureos generates revenue through traditional VC economics — management fees on committed capital and carried interest on realized returns — with returns generated via portfolio company IPOs and acquisitions. Notable exits include Araris Biotech (acquired by Taiho Pharmaceutical for up to $1,140 million in March 2025), ImCheck Therapeutics (acquired by Ipsen for up to €1 billion in December 2025), Corlieve Therapeutics (acquired by uniQure for up to €250 million in June 2021), and Acrivon Therapeutics (NASDAQ IPO in November 2022).

Pureos's go-to-market approach centers on direct equity investments in funding rounds sourced through industry networks, biotech conferences, and inbound inquiries, often leading or co-leading rounds alongside other life-sciences-focused VCs and strategic investors such as RA Capital, Forbion, Novartis Venture Fund, Johnson & Johnson Innovation, and Bpifrance. The firm maintains an ecosystem partnership with BaseLaunch, the Basel-area biotech accelerator, providing privileged access to early-stage deal flow. As a venture capital firm, Pureos does not sell products or services to end customers; rather, its "customers" are the founders and management teams of portfolio companies, whom the firm supports with capital, strategic guidance, and industry connections.

Name

Pureos Bioventures

Legal name

Pureos Partners AG

Website

http://www.pureosbio.com/en/

Company type

Private

Operating status

Operating

Headcount range

11–50 employees

Short description

Pureos Bioventures is a Swiss venture capital firm founded in 2017 that invests venture capital in private biotech companies developing next-generation biological drugs, including ADCs, TCR therapies, and gene therapies, targeting severe diseases.

Ownership category

akta.pro rank

Headquarters

HQ city

Küsnacht

HQ country

Switzerland

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Others

Revenue model

1. Fund Management and Investment Returns: Pureos Bioventures generates returns through its venture capital fund by investing in private biotech companies. The firm's revenue model is based on traditional VC economics: management fees from the fund (typically 2% of committed capital) and carried interest (typically 20% of profits above the hurdle rate). Returns are realized through portfolio company exits via IPOs or acquisitions. Notable exits include Araris Biotech (acquired by Taiho Pharmaceutical for up to $1,140 million), Corlieve Therapeutics (acquired by uniQure for up to €250 million), and ImCheck Therapeutics (acquired by Ipsen for up to €1 billion).

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

Pureos Bioventures is a Swiss venture capital firm that invests in private innovative drug development companies with an emphasis on next-generation biological drugs and drug formats. The firm deploys capital from its USD 205 million fund into biotech companies developing therapeutics for severe diseases, including antibody-drug conjugates, T-cell receptor therapies, radiopharmaceuticals, and gene therapies. The firm provides equity investment, strategic guidance, and industry expertise to portfolio companies from discovery through clinical stages.

Product overview

Pureos Bioventures is a venture capital firm that provides investment services to private innovative drug development companies. Rather than a unified software product, the firm offers financial investment and portfolio management focused on the next generation of biological drugs and drug formats. The company does not offer a technology platform or SaaS product—it is an investment firm that backs biotech companies developing innovative therapeutics for severe diseases.

Differentiator

Problem solved

Functional benefit

Products and services

• Pureos Bioventures Venture Capital Investment Services

Quantifiable outcome

• Araris Biotech acquired by Taiho Pharmaceutical for up to $1,140 million (March 2025)
• +3 more outcomes

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

One partnership is on record.

• BaseLaunch (Incubator/Accelerator)coreStrategic or Co-development PartnerBaseLaunch is the Basel area-based incubator and accelerator that helps scientists and entrepreneurs launch exceptional biotech companies in Switzerland. Pureos Bioventures is a partner/supporter of BaseLaunch, which has supported 27 biotech companies that have collectively raised over $1 billion. BaseLaunch embeds portfolio companies in the Basel Area, a major European biopharmaceutical hub. Partners include Pfizer, AbbVie, and Roche Venture Fund among seven pharmaceutical partners.

Scale indicators4 records

Recent moves7 records

Expansion highlights5 records

Direct peers

• Forbion Capital Partners: European life-sciences-focused VC firm investing across stages in biotech companies developing novel therapeutics. Direct peer to Pureos: co-invested with Pureos on Citryll's Series B and Adcytherix's Series A, and shares the European biotech focus, similar fund sizes, and similar stage of investment.
• Novo Seeds (Novo Holdings): Novo Holdings' early-stage life-sciences investment arm, focused on seeding and Series A biotech companies across Europe. Direct peer to Pureos: comparable fund size, stage focus, and European biotech investment mandate.
• Kurma Partners: European healthcare VC firm investing in biotech and digital health across early and growth stages. Direct peer to Pureos: co-invested with Pureos on Adcytherix's Series A and shares the European biotech focus with similar fund vintage size.
• Andera Partners: European life-sciences VC firm (formerly Edmond de Rothschild Investment Partners) with deep biotech focus. Direct peer to Pureos: co-invested with Pureos on Adcytherix's Series A and shares a similar European biotech mandate and stage orientation.
• BioGeneration Ventures (BGV): Dutch life-sciences VC firm focused on early-stage European biotech. Direct peer to Pureos: comparable fund size, stage focus on seed-to-Series A European biotech, and similar therapeutic-area breadth across oncology and rare diseases.
• LSP (Life Sciences Partners): Amsterdam-based life-sciences VC firm investing across stages in European biotech. Direct peer to Pureos: comparable European biotech mandate, similar fund vintage size, and overlap in therapeutic-area focus.
• Novartis Venture Fund: Corporate venture capital arm of Novartis investing in pharmaceutical, diagnostic and digital-health companies. Direct peer to Pureos: co-invested with Pureos on Citryll's Series B; comparable biotech-stage focus and European orientation.
• Boehringer Ingelheim Venture Fund: Corporate venture arm of Boehringer Ingelheim focused on early-stage biotech. Direct peer to Pureos: comparable European biotech investment focus and stage orientation; serves as co-investor and exit channel for European biotechs.

Broad incumbents

• Versant Ventures: Established global healthcare VC firm with multiple funds and broader geographic and stage reach than Pureos. Comparable as a biotech-focused VC peer; broader incumbent given larger fund sizes and longer track record across NA and Europe.
• Atlas Venture: Long-established biotech-focused VC firm with broader stage coverage and larger AUM than Pureos. Comparable in biotech-only focus and early-stage orientation, but operates as a broader incumbent given multi-decade history and US/UK presence.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/pureos-bioventures

Revenue estimate

Valuation estimate

Number of profiles

Profiles13 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments36 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Pureos Bioventures